Intratumoral Cellular Therapy with Autologous Activated M1 Sirpα-Low Macrophages In Non-Hodgkin Lymphoma: Clinical Results from a First-In-Human Phase 1 Study

Key Points

• Activated M1 macrophages may improve treatment outcomes in non-Hodgkin lymphoma, enhancing immune response.
• Clinical results indicate a favorable safety profile and signaling pathways activation within tumor microenvironments.
• Intratumoral cellular therapy was employed in a first-in-human phase 1 study, focusing on macrophage activation and interaction with cancer cells.
• Future research may confirm the significance of combined therapies to increase efficacy; further studies are suggested.